Aprea Therapeutics, Inc.
APRE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | -$0 | -$0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -98.4% | -27.3% | -21.1% | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | -193.8% | -1,519% | -1,428.4% | -1,046.2% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -160,550.9% | -2,863.7% | -2,511.4% | -1,564.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -160,844.7% | -2,742.2% | -2,420.6% | -1,406.5% |
| EPS Diluted | -0.47 | -0.53 | -0.66 | -0.49 |
| % Growth | 11.3% | 19.7% | -34.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |